Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Fox Chase Cancer Center, Department of Radiation Oncology report on findings in cancer gene therapy
June 3rd, 2008
Researchers detail in 'Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo,' new data in cancer gene therapy. "Antisense MDM2 oligonucleotide (AS-MDM2) sensitizes androgen sensitive LNCaP cells to androgen deprivation (AD) in vitro and in vivo. In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells," scientists in the United States report. "The LNCaP-Res cell line was generated by culturing LNCaP cells in medium containing charcoal-stripped serum for more...
Source: Cancer Weekly (2008-06-03)
|
